Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

Abstract: A computer-implemented method, system, and medium are disclosed for implementing a hybrid application server. The server comprises an application server container, a dynamic module system, and a resources-exporter module deployed on the dynamic module system. The resources-exporter module is configured to detect that a system-level resource of the application server container has been deployed. In response to detecting that the container resource has been deployed, the resources-exporter is configured to register a proxy object for the system-level resource as a service in the dynamic module system.

Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

Abstract: A computer-implemented method, system, and medium are disclosed for implementing a hybrid application server. The server comprises an application server container, a dynamic module system, and a resources-exporter module deployed on the dynamic module system. The resources-exporter module is configured to detect that a system-level resource of the application server container has been deployed. In response to detecting that the container resource has been deployed, the resources-exporter is configured to register a proxy object for the system-level resource as a service in the dynamic module system.

Abstract: A method for detection of non-portable application programming interface usage via executable code analysis includes identifying one or more conditions for inclusion of an object class within a set of acceptable object classes, wherein a reference to any object class of the set of acceptable object classes by an application is in compliance with a specified portability criterion. The method further includes analyzing an executable version of the application to identify object classes referenced by the application, and generating a portability verification report for the application, wherein the report indicates that the application violates the specified portability criterion if an object class referenced by the application does not meet at least one of the conditions for inclusion in the set of acceptable classes.

Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

Abstract: A system and for dynamic verification of application portability may include an application server configured to support a debugging interface, an application deployed on the application server, and a portability verification tool. The portability verification tool may be configured to invoke the debugging interface during an execution of the application to determine whether the application violates one or more specified portability criteria during the execution.

Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

Abstract: The present invention relates to a transferrin-conjugated nanoparticle composition with sustained release characteristics. A method for increasing the efficacy of therapeutic agents and a method for treating cancer using the transferrin-conjugated nanoparticle composition are also provided.